360 ONE Asset, a prominent asset management company in India, has invested in OneSource Specialty Pharma, a rapidly expanding and specialized pharma CDMO (contract development and manufacturing organization). This strategic acquisition involved purchasing a stake from an existing investor, aligning with OneSource’s ambitious growth phase as it positions itself as a leader in biologics, drug-device integrations, advanced injectables, and soft gelatin capsules.
OneSource is uniquely positioned to meet the rising demand for these specialized pharmaceutical solutions, thanks to strong partnerships with renowned global pharma and biotech companies. As one of the few Indian firms capable of developing and producing sophisticated products such as GLP-1 drugs and new biologics, it continues to reinforce its market leadership. With five high-tech manufacturing facilities, including four that have received US FDA approval and boast exemplary compliance records, backed by a team of over 1,200 professionals—over 100 being scientists and techno-commercial experts—OneSource is geared for considerable expansion.
Tarun Sharma, the Healthcare and Consumer Fund Manager at 360 ONE Asset, mentioned, “We are supporting OneSource, which has cultivated an extensive range of capabilities. The company’s prowess in large molecule products, complex injectables, and integrated drug-device solutions places it on a path for its next growth chapter. We are excited to partner with OneSource as they advance their journey of innovation and global outreach.”
Neeraj Sharma, CEO of OneSource Specialty Pharma, stated, “Our proficiency in niche and complex dosage forms, along with our outstanding compliance record, allows us to offer comprehensive, all-encompassing solutions to our international clientele. We are thrilled to have 360 ONE Asset as an investor who shares our vision to scale new heights.”